References
- Thomassen M, Hansen TVO, Borg Å, et al. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncol. 2008;47:772–777.
- Sønderstrup IMH, Laenkholm AV, Jensen MB, et al. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. Acta Oncol. 2018.
- Plon SE, Eccles DM, Easton D, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–1291.
- Spurdle AB, Healey S, Devereau A, et al. ENIGMA-evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat. 2012;33:2–7.
- Goldgar DE, Easton DF, Deffenbaugh AM, et al. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet. 2004;75:535–544.
- Walker LC, Whiley PJ, Couch FJ, et al. Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Hum Mutat. 2010;31:E1484–E1505.
- Spurdle AB, Lakhani SR, Healey S, et al. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis–a report from the kConFab Investigators. J Clin Oncol. 2008;26:1657–1663.
- Spearman AD, Sweet K, Zhou XP, et al. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol. 2008;26:5393–5400.
- Osorio A, Milne RL, Honrado E, et al. Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information. Hum Mutat. 2007;28:477–485.
- Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 2007;81:873–883.
- Gómez García EB, Oosterwijk JC, Timmermans M, et al. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res. 2009;11:R8.
- de la Hoya M, Soukarieh O, López-Perolio I, et al. Combined genetic and splicing analysis of BRCA1 c.[594-2A > C; 641A > G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Hum Mol Genet. 2016;25:2256–2268.
- Anczuków O, Buisson M, Léoné M, et al. BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy. Clin Cancer Res. 2012;18:4903–4909.
- den Dunnen JT, Dalgleish R, Maglott DR, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37:564–569.
- ClinVar [Internet].USA: NCBI;[cited 2017 August 16]. 2013. Available from: https://www.ncbi.nlm.nih.gov/clinvar/
- Whiley PJ, de la Hoya M, Thomassen M, et al. Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing. Clin Chem. 2014;60:341–352.